Fierce Pharma Asia—AbbVie’s bispecific play, Illumina’s China import efforts and pharma execs’ JPM comments Fierce Pharma Politics
Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe’s ALS business Fierce Pharma Economics
Top China Pharma and Biotech Stocks to Watch, According to Bernstein Investing.com Politics
Hutchmed’s savolitinib NDA accepted for China priority review The Pharma Letter Politics
SGD Pharma Earns China’s first ISO 14021 PCR Glass Certification Packaging Digest Politics
Urgent action needed to maintain US global leadership over China in biotech innovation The Pharma Letter Politics
If pharmaceutical drug patents are an hourglass turned over on the day of approval – with the approaching loss of exclusivity known in the industry as the “patent cliff” – then Big Pharma is currently watching the final grains of sand slipping through the neck of the glass. At the bottom of the hourglass awaits an unforgiving world of generic and biosimilar competition. Between 2025 and 2030, the patent cliff is set to be one of the biggest since 2010 by revenue at risk, according to... Science
Will China biotech be a hard pill to swallow for US Big Pharma? South China Morning Post Science
Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’? South China Morning Post Science
